|
|
|
|
 |
|
SENSEX
|
 |
-456.53
|
-0.63%
|
|
71569.62
|
|
|
|
NIFTY
|
|
-141.60
|
-0.65%
|
|
21569.20
|
|
|
|
Nasdaq
|
 |
13.77
|
0.09%
|
|
14524.07
|
|
|
|
Nikkei 225
|
|
89.13
|
0.27%
|
|
33377.42
|
|
|
|
FTSE 100
|
|
-33.50
|
-0.43%
|
|
7689.60
|
|
|
 |
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04-01-2024
|
|
|
|
| Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
|
|
04-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is saf |
|
|
|
|
|
04-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Suven Life Sciences Limited has submitted their response. |
|
|
|
|
|
03-01-2024
|
|
|
|
| Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
|
|
03-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Suven Life Sciences Limited has submitted their response. |
|
|
|
|
|
03-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
|
|
|
|
02-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is saf |
|
|
|
|
|
02-01-2024
|
|
|
|
| Significant increase in volume has been observed in Suven Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
|
|
|
|
29-12-2023
|
|
|
|
| Suven Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
|
|
|
|
29-12-2023
|
|
|
|
| SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Closure of Trading Window |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|